AnteoTech Limited (ADO.AX) Stock Analysis & Winston Score
AnteoTech is a small Australian biotechnology and specialty chemicals company. It makes a material called AnteoBind, a coating technology that helps other molecules stick together more reliably. Its main customers are companies that make diagnostic tests — the kind used in hospitals and labs to detect diseases, infections, or other health conditions. AnteoTech also develops its own rapid diagnostic tests, including tests for influenza and COVID-19. The company earns money by licensing its AnteoBind technology to diagnostic manufacturers and by selling test kits directly. It is based in Brisbane, Australia, and operates at a very small scale, with a market value around $100 million. The unusually high gross margin reflects the licensing model, but the negative return on invested capital shows the company is still spending more than it earns overall. The key risk is that AnteoTech must successfully convert licensing partnerships into steady, recurring revenue before it runs through its cash reserves.
Winston Score: 0/100 — Insufficient Data
Not enough data to score this stock reliably.
- Quality: Weak (1/30)
- Growth: Mixed (7/20)
- Cash Flow: Data not available (0/10)
- Stability: Mixed (3/10)
- Valuation: Data not available (0/10)
- Ownership: Good (10/15)

